The groups behind the petition include the American College of Obstetricians and Gynecologists, SisterReach, Physicians for Reproductive Health and the Expanding Medication Abortion Access Project. To clear access to the FDA-approved medication, the petition asks the FDA to submit a Supplemental New Drug Application or “eliminate or modify mifepristone’s Risk Evaluation and Mitigation Strategy so that it is not unduly burdensome for that use.”
After the Supreme Court overturned Roe v. Wade in June, access to mifepristone waned as pharmacies and health systems scrambled to understand new laws. As a result of the landmark decision, in some states, CVS policy requires workers to confirm a patient’s mifepristone prescription is not intended for abortion.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
